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Figures 1.1 – 1.2. Representative experiment investigating the 
significance of mutations in the hormone-binding domain of 
VDR on receptor activity. Using a VDRE (PER6)-luciferase 
reporter assay, identical hormone treatments were applied to cells 
transfected with “wild-type” VDR and to VDR with a single mutation 
in the hormone-binding pocket (R274L), eliminating the ability of 
the receptor to bind to vitamin D. The 57% drop in resveratrol only 
activity between WT and mutant R274L VDR (Fig 5.1), compared 
to the 98% drop in 1,25D-mediated transcription or the 96% reduc-
tion in 1,25D+resveratrol-mediated activity (Fig. 5.2) suggests the 
possibility of another pathway for resveratrol action besides direct 
binding in the VDR ligand pocket.  Similar results were obtained 
with another VDR hormone binding mutant (C288G; data not 
shown).
Figure 2. Competitive binding assay. Radiolabeled 1,25D was used to determine if resveratrol 
could compete with 1,25D for binding to the vitamin D binding pocket. DHA, a known VDR ligand, was 
used as positive control and dexamethasone, a non-VDR ligand was used as a negative control.  
When cell lysates containing VDR were treated with increasing concentrations of resveratrol, bound 
radiolabeled 1,25D actually increased.  This suggests resveratrol may “stabilize” the 1,25D-VDR com-
plex, as opposed to competing with 1,25D for the binding pocket as initially predicted. 
Figures 3.1 - 3.2. Resveratrol induced transcriptional acti-
vity in a variety of nuclear receptors. A number of response 
elements (ERE, RARE, GRE, RXRE, PXRE, LXRE) in conjunc-
tion with a luciferase reporter system were employed to measu-
re nuclear receptor activation by 3.3x10-5 M resveratrol. The 
resulting transcriptional activity is described as the fold-effects 
over the negative (vehicle) control (not displayed). The cell 
lines tested are HCT116 (A) and HEK293 (B).
Figures 3.3 - 3.4. The potential for synergistic activity bet-
ween resveratrol and the respective ligands of a variety of 
nuclear receptors. The indicated response elements (VDRE, 
ERE, RARE, GRE, RXRE, PXRE, LXRE) in conjunction with a 
luciferase reporter system were used to measure receptor acti-
vation by the respective ligand (in brackets), and any additional 
stimulation upon combining the respective ligand with 3.3x10-5 
M resveratrol. Ligand concentrations used were 10-6 (ER, GR, 
RXR, LXR), 10-7 (RAR, PXR), and 10-9 (VDR). The transcripti-
onal activity is described as fold-effects over the negative con-
trol (vehicle).
vitamin D responsive elements (VDREs) located in the vicinity of target 
genes. Upon activation by 1,25D or other ligand(s), (2) VDR also binds to 
coactivators with histone acetyl transferase (HAT) activity, such as SRC-1.  
(3) Activated VDR recruits, and delivers to RNA polymerase II, basal 
transcription factors such as TFIIB.  VDR also binds to D-receptor interac-
ting proteins (DRIPs) which anchor a mediator complex that interacts with 
RNA polymerase II.  (4) Holo RNA polymerase II acts to initiate the 
transcription of vitamin D target genes, some of which are highlighted in red 
at the lower right.
Figure 2. A transcriptional 
assay (A) measures how 
effectively a ligand induces 
receptor activation and 
transcriptional activity. The 
responsive element reporter 
constructs used to evaluate 
resveratrol for receptor-ligand 
binding and/or activation 
included the vitamin D res-
ponse elements (VDRE), the 
estrogen response element 
(ERE), retinoic acid response 
element (RARE), glucocorticoid responsive element (GRE), retinoid X 
receptor responsive element (RXRE, shown in Fig. 2), pregnane X-receptor 
response element (PXRE), and liver X receptor response element (LXRE).  
The mammalian two-hybrid assay (B) detects the affinity of the ligand for the 
receptor and the ability of the ligand to induce dimerization. This system was 
used to test resveratrol modulation of VDR-RXR dimerization (binding of 
VDR-AD to RXR-BD), and recruitment of coactivators by VDR-AD, followed 
by activation of the luciferase gene (results not shown).  
Abstract
The nuclear vitamin D receptor (VDR) modulates gene transcription in 
1,25-dihydroxyvitamin D (1,25D) target tissues such as kidney, colon, and 
bone. The 1,25D hormone is derived from vitamin D in the skin or from the 
diet, and binds to and activates the VDR.  We have previously shown that 
resveratrol, an antioxidant found in the skin of red grapes, has the ability to 
activate the VDR signaling pathway. Moreover, cells treated with both resve-
ratrol and 1,25D resulted in an additive or even synergistic stimulation of 
VDR-mediated transcription compared to cells treated with 1,25D alone.  
Based on these initial results, experiments were designed to test the signifi-
cance of mutations in the hormone-binding domain of VDR. Identical hormo-
ne treatments were applied to “wild-type” (non-mutated) and single point 
VDR mutations. 1,25D displayed a significant drop in activity caused by 
these mutations, while the ability of resveratrol to activate VDR was only 
modestly attenuated. One possible interpretation of these results is that res-
veratrol may affect VDR activity indirectly, perhaps via the ability of resve-
ratrol to activate SIRT1, an enzyme which has been shown to deacetylate 
(and thereby activate) other nuclear receptors such as the liver X receptor 
(LXR). In support of this hypothesis, radiolabeled 1,25D displacement 
assays revealed an increase in bound radiolabeled 1,25D only in the pre-
sence of resveratrol, suggesting that direct binding of resveratrol to VDR is 
unlikely. Additionally, we observed increased transcriptional activity in res-
ponse to resveratrol in a subset of other nuclear receptors, including the 
liver X receptor (LXR), which is closely related to VDR and is known to be 
deacetylated by SIRT1. Finally, we tested receptor-mediated transcriptional 
activity in a system containing VDR in the absence and presence of overex-
pressed SIRT1. Transcriptional activity was higher in cells expressing 
SIRT1, and synergistic activity of 1,25D combined with resveratrol was ob-
served. We are currently conducting additional experiments employing the 
VDR/SIRT1 assay in multiple cellular contexts. In conclusion, this study elu-
cidates, for the first time, a potential novel pathway for "crosstalk" between 
two nutritionally derived lipids, vitamin D and resveratrol.
Results
Background
Figure 1. A working model 
for transcriptional control 
by 1,25D in which (1) the 
hormone (1,25D or other 
potential ligands such as 
resveratrol, indicated by the 
red circle) move into the nu-
cleus of the cell and bind 
directly to VDR, initiating sti-
mulation of VDR activity. Ac-
tivated VDR then dimerizes 
with a retinoid X receptor 
(RXR) and binds to specific 
Methods
Conclusions
1,25D and resveratrol are non-competitive activators of the nuclear vitamin 
D receptor (VDR). When combined, 1,25D and resveratrol exhibit an additive 
or synergistic effect on VDR transactivation.
Resveratrol may function as an indirect activator of the VDR by stimulating 
SIRT1, which may consequently lead to SIRT1-mediated modification of 
VDR (deacetylation) that causes further stimulation of the receptor.
The indirect activation of VDR via the SIRT1/deacetylation pathway repre-
sents a novel form of post-translational regulation of the VDR.  The activity 
of other nuclear receptors may also be controlled by this pathway.
Future Directions
We will continue to test VDR deacetylation by SIRT1 as follows:
 treating cells with resveratrol (which will activate SIRT1) to determine if 
 SIRT+resveratrol can stimulate VDR activity in a SIRT-dependent
  manner.
 transfecting several different cell lines with various amounts of VDR and 
 SIRT1 to probe the cell-specific effects of SIRT1/resveratrol on VDR 
 activity.
 test the dose response of resveratrol and 1,25D in terms of their 
 synergistic activation of VDR
 evaluate the acetylation status of immunopurified VDR from SIRT1 and 
 resveratrol treated cells.  Since acetylated VDR migrates more slowly 
 than de-acetylated VDR during SDS-PAGE due to differences in 
 molecular weight, analysis of VDR immunoprecipitates will allow for the 
 examination of VDR acetylation status after resveratrol or SIRT1 
 treatment.  We will also employ anti-acetyl-lysine antibodies to probe 
 the acetylation state of VDR.
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Figure 4. Evaluation of SIRT1 expression on transcriptional activity induced by 1,25D and resveratrol. HEK293 cells 
were transfected with a VDR expression plasmid along with an expression vector for SIRT1 (pSG5-SIRT1) or the empty parent 
vector (pSG5) as a negative control.  After 24 hours of transfection, the cells were refed with fresh medium containing either 
1x10-8 M 1,25D, 2.5x10-5 M resveratrol, a combination of both compounds, or ethanol vehicle.   Transcriptional activity was 
measured using a Dual-Luciferase Reporter (DLR) Assay system, and reported as normalized relative light units (RLU). Re-
sults indicate increased transcriptional activity in the presence of SIRT1 and synergistic activity between 1,25D and 
resveratrol. 
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